We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

143 hedge funds and large institutions have $797M invested in Arcutis Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 32 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

254% more call options, than puts

Call options by funds: $3.99M | Put options by funds: $1.13M

113% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 32

10% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 20

8.72% more ownership

Funds ownership: 108.46% → 117.18% (+8.7%)

1% more funds holding

Funds holding: 141 → 143 (+2)

18% less capital invested

Capital invested by funds: $974M → $797M (-$177M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
143
Holders Change
+2
Holders Change %
+1.42%
% of All Funds
2.28%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
22
Increased
68
Reduced
32
Closed
20
Calls
$3.99M
Puts
$1.13M
Net Calls
+$2.86M
Net Calls Change
-$8.25M

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$33.4M
2
Bank of America
Bank of America
North Carolina
+$20M
3
PCH
Polar Capital Holdings
United Kingdom
+$16.3M
4
Holocene Advisors
Holocene Advisors
New York
+$13.4M
5
Jennison Associates
Jennison Associates
New York
+$11.8M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$20.7M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16.3M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$10.1M
4
Millennium Management
Millennium Management
New York
-$9.83M
5
CAM
Cormorant Asset Management
Massachusetts
-$9.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$5.58M -$1.05M -72,870 -13%
OM
27
Opaleye Management
Massachusetts
$5.52M +$7.26M +502,000 New
Ensign Peak Advisors
28
Ensign Peak Advisors
Utah
$5.35M +$24.4K +1,688 +0.3%
Axa
29
Axa
France
$4.87M +$1.54M +106,693 +32%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$4.82M +$978K +67,625 +18%
EC
31
EcoR1 Capital
California
$4.57M – – –
Northern Trust
32
Northern Trust
Illinois
$4.26M +$29.1K +2,009 +0.5%
Morgan Stanley
33
Morgan Stanley
New York
$3.71M +$2.02M +139,590 +70%
SAM
34
Sectoral Asset Management
Quebec, Canada
$3.49M +$1.64M +113,300 +56%
Rafferty Asset Management
35
Rafferty Asset Management
New York
$3.35M +$22.8K +1,577 +0.5%
Charles Schwab
36
Charles Schwab
California
$3.33M +$11.2K +774 +0.3%
SEI Investments
37
SEI Investments
Pennsylvania
$3.01M +$3.96M +273,599 New
Citadel Advisors
38
Citadel Advisors
Florida
$2.99M +$3.79M +261,888 +2,719%
MB
39
MPM BioImpact
Massachusetts
$2.8M -$115K -7,932 -3%
Goldman Sachs
40
Goldman Sachs
New York
$2.72M -$473K -32,689 -12%
Citigroup
41
Citigroup
New York
$2.68M +$1.6M +110,771 +83%
Parallax Volatility Advisers
42
Parallax Volatility Advisers
California
$2.49M +$2.36M +163,137 +258%
1CM
43
1492 Capital Management
Wisconsin
$2.46M +$708K +48,970 +28%
CC
44
Centiva Capital
New York
$2.2M +$2.89M +200,000 New
AA
45
AlphaCentric Advisors
Puerto Rico
$2.09M +$1.61M +111,500 +142%
Neuberger Berman Group
46
Neuberger Berman Group
New York
$2.01M +$241K +16,637 +10%
SVCM
47
Saturn V Capital Management
Texas
$1.96M -$4.47M -308,962 -63%
Prudential Financial
48
Prudential Financial
New Jersey
$1.79M +$954K +65,975 +68%
PP
49
PDT Partners
New York
$1.71M +$1.41M +97,607 +169%
TCM
50
Tekla Capital Management
Massachusetts
$1.64M – – –
1
2
3 4 5

ARQT Hedge Fund Activity: Q1 2023 in Review

143 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2023, worth a combined $797M — down 18% from $974M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ARQT positions and 20 closed out — a net gain of 2 holders — while 68 added to existing stakes and 32 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $33.4M. The largest seller was Logos Global Management, exiting entirely with an estimated $20.7M sold.

  • 143 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2023, up from 141 in Q4 2022.
  • Funds reported $797M of Arcutis Biotherapeutics stock for Q1 2023, down 18% quarter-over-quarter.
  • 22 funds opened new Arcutis Biotherapeutics positions in Q1 2023 and 20 closed out, a net change of +2 holders.
  • The largest Arcutis Biotherapeutics buyer in Q1 2023 was Marshall Wace, an estimated $33.4M added.
  • The largest Arcutis Biotherapeutics seller in Q1 2023 was Logos Global Management, an estimated $20.7M sold.

Based on aggregated 13F filings for Q1 2023.